Cite
HARVARD Citation
Maher, T. et al. (2023). Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet. 11 (1), pp. 45-54. [Online].